All posts by imreal

Science: Biology

Absolute Antibody Launches VivopureX™ Recombinant Antibodies for In Vivo Research

Leave a comment


News Image

The VivopureX™ antibody collection includes a selection of our most exciting mouse-anti-mouse antibodies, now available at discounted bulk prices ideal for in vivo researchers.


REDCAR, United Kingdom (PRWEB)

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced the launch of its VivopureX™ recombinant mouse antibodies for in vivo research in mouse models. The collection consists of popular antibody clones, many originally obtained from rats or hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant versions to improve research results. The antibodies are all available in discounted bulk sizes ranging from 1 mg to 100 mg.

VivopureX™ antibodies are species-matched chimeric antibodies, consisting of a clone’s original antigen-binding variable domain with a mouse constant domain, which means they do not induce neutralizing antibodies in mouse models. As a result, the engineered recombinant antibodies offer many advantages compared to the original monoclonal antibodies, including increased long-term efficacy, stronger potency and a more consistent response across cohorts. In addition, VivopureX™ antibodies feature engineered effector functions, with Fc receptor binding tailored to best suit popular applications such as depletion, agonism or blocking.

All antibodies are produced recombinantly for ensured batch-to-batch reproducibility, and offer high purity and low endotoxin levels ideal for in vivo applications. The antibodies are targeted against key immune system proteins, including clinically relevant checkpoint proteins such as PD-1, CTLA-4 and OX40. Absolute Antibody data has shown that the recombinant mouse PD-1 antibody, based on the widely used clone RMP1-14, reduces tumor size in a mouse model more effectively than the original rat version.

“The VivopureX™ antibody collection includes a selection of our most exciting mouse-anti-mouse antibodies, now available at discounted bulk prices ideal for in vivo researchers,” said Dr. Michael Fiebig, Director of Products and Innovations at Absolute Antibody. “Most antibodies currently used in vivo are immunogenic, leading to adverse immunological reactions and gradual loss of activity. By applying the same protein engineering approaches used in therapeutic development to research reagents, we can improve in vivo research results and further our understanding into the mechanisms underlying immunotherapy.”

For more information, and a full list of available antibody targets, please visit our website here.

About Absolute Antibody, Ltd.

Absolute Antibody is a rapidly growing company with a vision to make recombinant antibody technology accessible to all. We offer antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies, engineered into new and useful formats. Visit absoluteantibody.com for more information.

Contact:

Lisa Merolla    

Director of Marketing

+1 617-377-4057 (extension 610)

l.merolla@absoluteantibody.com

Share article on social media or email:

Technology: Electronics

Zonar Announces Availability of Cummins Connected Software Updates and Mobile App Provisioning

Leave a comment


Zonar OTAir

The availability of Cummins Connected Software Updates through Zonar’s OTAir app allows customers with Cummins engines more control and convenience over the performance and management of their fleets, saving time and costs associated with traditional calibration methods


SEATTLE (PRWEB)

Zonar, the leader in smart fleet technology, announced today the availability of Cummins Connected Software Updates, an over-the-air programming solution for maximizing uptime and performance of Cummins powered vehicles. This solution allows fleet managers and drivers who use Zonar telematics services to manage and deliver over-the-air programming to their Cummins engines using Zonar OTAir, an easy to use app on their smartphone. Fleets that use Cummins Connected Software Updates receive the latest performance enhancements from Cummins by using OTAir, resulting in reduced downtime, increased cost savings and improved vehicle health – without the need of any additional hardware.

Cummins Connected Software Updates empowers fleet managers and drivers with flexibility and an additional level of control over their vehicles. Similar to smartphones and computers, a fleet’s engines also require regular updates. These updates are typically centered around specific performance improvements that help ensure a fleet’s vehicles are always running at peak performance. With Connected Software Updates, fleet managers and drivers can perform engine software updates on a single vehicle or fleet of vehicles while on the road, allowing customers to scale and expedite service needs. While traditional calibration updates can take up to two days and cost hundreds of dollars in labor, updates through Cummins Connected Software Updates can take as little as five minutes from start to finish with no associated labor costs when using OTAir.

“The availability of Cummins Connected Software Updates through Zonar’s OTAir app allows customers with Cummins engines more control and convenience over the performance and management of their fleets, saving time and costs associated with traditional calibration methods,” said Todd Mysak, Director Business Development at Cummins Inc. “The collaboration between Zonar and Cummins helps us deliver on our commitment to provide innovative solutions that ensure fleets with Cummins engines perform at optimal levels.”

With Cummins Connected Software Updates, fleets using Zonar with Cummins engines can improve their operations through the following benefits:


  • Reduce downtime – With over-the-air updates, vehicles can spend more time on the road than at the shop receiving updates

  • Cost savings – A typical shop visit for an engine calibration update can cost in excess of $110 per visit, per vehicle

  • Increased vehicle health – With up-to-date software, vehicles run more efficiently and safely

  • Ease-of-use – Drivers can quickly approve updates on their smart phone or tablet and start the over-the-air process without hassle

  • Rapid updates – Fleet managers and drivers can work together to find optimal times, such as a driver’s 30 minute rest break, to complete updates in as little as five minutes

  • Increase fleet control – Fleet managers are notified through the Cummins portal of available updates for specific engines, allowing them to schedule updates appropriately

  • Data security – OTAir includes VIN validation to help ensure the correct vehicle is receiving the correct update.

“With Cummins Connected Software Updates, over-the-air programming for commercial vehicles is no longer a future concept,” said Gary Schmidt, Vice President of Business Solutions at Zonar. “Through our ongoing collaboration with Cummins, we’re bringing a smartphone accessible solution to market that helps fleets eliminate the need to schedule shop visits for calibrations. We believe this will help spur the creation of broader industry innovations focused on reducing the time spent by fleets waiting for updates.”

For more information on Cummins Connected Software Updates available through Zonar, please visit: https://www.zonarsystems.com/blog/pressreleases/zonar-announces-availability-of-cummins-connected-software-updates/

About Zonar

Founded in 2001, Zonar has pioneered smart fleet management solutions throughout vocational, pupil, mass transit and commercial trucking industries. Zonar’s mission is to enhance the safety, performance and success of our customers by transforming the delivery of innovative insights for commercial fleets around the world. Zonar achieves this by helping fleets of all sizes maximize the use of their assets with solutions dedicated to improving compliance, efficiency, maintenance, ridership visibility, safety and tracking. Cloud-based services with open APIs drive Zonar’s smart fleet solutions by making it easy for fleet owners and managers to stay connected to their fleets and drivers and operators to dispatch. Headquartered in Seattle and majority-owned by technology company Continental, Zonar also has a Technology Development Center in downtown Seattle, a regional office in Cincinnati, and a distribution center outside of Atlanta. For more information about Zonar, go to http://www.zonarsystems.com

About Cummins Inc.

Cummins Inc., a global power leader, is a corporation of complementary business units that design, manufacture, distribute and service a broad portfolio of power solutions. The company’s products range from diesel and natural gas engines to hybrid and electric platforms, as well as related technologies, including battery systems, fuel systems, controls, air handling, filtration, emission solutions and electrical power generation systems. Headquartered in Columbus, Indiana (U.S.A.), since its founding in 1919, Cummins employs approximately 62,600 people committed to powering a more prosperous world through three global corporate responsibility priorities critical to healthy communities: education, environment and equality of opportunity. Cummins serves customers in approximately 190 countries and territories through a network of approximately 600 company-owned and independent distributor locations and over 7,600 dealer locations and earned about $2.1 billion on sales of $23.8 billion in 2018.

See how Cummins is powering a world that’s Always On by accessing news releases and more information at https://www.cummins.com/always-on. Follow Cummins on Twitter at https://twitter.com/cummins and on YouTube at [https://www.youtube.com/user/CumminsInc.

Share article on social media or email:



health and fitness

Highmark Fights Opioid Stigma, Promotes Workplace Recovery with Shatterproof

Leave a comment


Our collaboration with Shatterproof will help fight stigma so that opioid use disorder is viewed as a chronic disease, rather than a moral failing. –Highmark president Deb Rice-Johnson


Pittsburgh, Pennsylvania (PRWEB)

Highmark announced that its employer-based members have access to new virtual education and advocacy tools that combat stigma associated with opioid use disorder (OUD) and promote recovery in the workplace. These new resources, which are a value-added service for Highmark group customers in Pennsylvania, Delaware and West Virginia, are offered in collaboration with Shatterproof. Shatterproof is a national nonprofit organization dedicated to reversing the addiction crisis in the U.S.

“Across the communities that we serve, we found that stigma associated with opioid use disorder is widespread,” says Highmark president Deb Rice-Johnson. “And yet, despite that stigma, we found that people want to help someone who is struggling with opioid dependence. Our collaboration with Shatterproof will help fight stigma so that opioid use disorder is viewed as a chronic disease, rather than a moral failing. It will also equip workplaces and our members with the knowledge and resources to start a conversation about opioids and help those in need.”

Through Shatterproof, Highmark’s employer-based members can engage in brief, interactive education modules that explore the science of opioid use disorder; environmental and genetic risk factors; the dangers of opioids; signs, symptoms and evidence-based treatment options; ways to help individuals and families challenged by OUD; and success stories of individuals who are in recovery.

These modules, which take around five minutes each to complete, also provide supplemental videos, fact sheets and other evidence-based resources for those who want a deeper dive on each subject.

“As the opioid crisis has evolved, so has our response,” says Dr. Caesar DeLeo, vice president and executive medical director of strategic initiatives for Highmark. “We remain committed to helping the members and communities that we serve at all stages—from fighting stigma, to preventing dependence, to accessing treatment, to promoting long-term recovery that allows individuals to return to their family lives and the workforce.”

For more information, please visit: https://justfive.org/highmarkblueshield/

The collaboration with Shatterproof is a response to the results of a 2019 community survey that Highmark conducted in each of its core health insurance markets in Pennsylvania, Delaware and West Virginia to better understand the public’s attitudes toward and experiences with opioid dependence. In each of Highmark’s core markets, more than 80 percent of survey respondents said that opioid dependence is mostly or somewhat the fault of the person. Additionally, more than three-quarters of respondents in all markets said that it is important for them to encourage friends, family members or acquaintances to seek care for opioid dependence.

Substance use disorders have wide-ranging consequences for employers, creating challenges related to decreased workplace safety and productivity, increased health care costs, absenteeism, turnover and a smaller pool of available talent. Substance use disorders have an estimated economic impact of more than $400 billion annually in the U.S., according to the National Safety Council (NSC). Large U.S. employers spent more than $2.5 billion annually in recent years on treatment for OUD and opioid overdoses. More than two-third of individuals with OUD are in the workforce, according to the NSC.

The collaboration with Shatterproof continues Highmark’s leadership in responding to the opioid crisis with a comprehensive approach that emphasizes primary prevention, safe prescribing and community supports.

Highmark has implemented a progressively intensive strategy to address the opioid crisis. The first component focuses on prevention by offering effective, non-pharmaceutical pain management therapies at the site of care. The second component of Highmark’s strategy emphasizes safe opioid utilization through new evidence-based medication policies, as well as ongoing monitoring and educational efforts for both members and prescribers. Highmark uses a data-driven approach to monitor members’ prescribing patterns and identify potentially unsafe use of opioids and other controlled substances. The third component centers on identifying members with opioid use disorder and linking them with high-quality, accessible treatment programs. Through these efforts, Highmark has reduced its members’ use and duration of use of opioids.

Throughout the past three years, Highmark and the Highmark Foundation have provided $3 million to community organizations and programs fighting the opioid epidemic in Pennsylvania, Delaware and West Virginia. Recently, Highmark’s Financial Investigations and Provider Review Team was honored with the National Health Care Anti-Fraud Association’s Excellence in Public Awareness Award for its Opioid Epidemic Education Program. Through that program, more than 6,500 students, parents and educators in western PA have been empowered with knowledge and resources to respond to opioid dependence in their communities.

About Highmark Inc.

One of America’s leading health insurance organizations and an independent licensee of the Blue Cross Blue Shield Association, Highmark Inc. (the Health Plan) and its affiliated health plans (collectively, the Health Plans) work passionately to deliver high-quality, accessible, understandable, and affordable experiences, outcomes, and solutions to customers. As the fourth-largest overall Blue Cross Blue Shield-affiliated organization, Highmark Inc. and its Blue-branded affiliates proudly cover the insurance needs of 4.5 million members in Pennsylvania, Delaware, and West Virginia. Its diversified businesses serve group customer and individual needs across the United States through dental insurance, vision care and other related businesses. For more information, visit http://www.highmark.com.

###

Share article on social media or email:

Industry: Healthcare

HealthSherpa enrolls over 1 million Americans during Open Enrollment Period

Leave a comment



SAN FRANCISCO (PRWEB)

With the close of the open enrollment period in the 38 states using the federal health insurance Marketplace, HealthSherpa announced its 2020 open enrollment results.

Between November 1st and December 17th, 2019, HealthSherpa enrolled 1.2 Million people in ACA coverage – a 143% increase over the prior Open Enrollment period. Over 31,000 of these enrollees were able to take advantage of the deadline extension granted by the Centers for Medicare and Medicaid Services. In total, HealthSherpa accounted for over 14% of ACA enrollments across the 38 Federal Marketplace states.

Most HealthSherpa consumers found coverage for $47/month or less, and 72% enrolled in silver plans, which offer comparable coverage to employer-sponsored health insurance. In aggregate, HealthSherpa has enrolled over 3 million Americans in on-exchange health insurance since 2014.

HealthSherpa is one of a handful of companies approved to use the Department of Health and Human Services’ innovative new Enhanced Direct Enrollment (EDE) technology, and was the first company granted approval on November 28th, 2018. In the 2020 Open Enrollment Period, HealthSherpa hosted the EDE platform for 37,000 insurance agents and over 15 insurance carriers.

EDE permits private companies to carry out all enrollment and related activities for on-exchange health coverage. HealthSherpa is approved for Phase 3, which allows HealthSherpa to process all applications, including those for rare tax circumstances, end-to-end on HealthSherpa.com.

“Continued strong enrollment year over year shows that consumers and issuers alike are deeply invested in the ACA Marketplace,” said HealthSherpa CEO George Kalogeropoulos. “Technologies like Enhanced Direct Enrollment are making it easier than ever for issuers, agents, employers, and other stakeholders to help Americans enroll in comprehensive coverage, and to help them manage that coverage throughout the year. We are proud to be at the forefront of ACA enrollment and to have the privilege of helping millions of Americans access the peace of mind that can only come with high-quality, ACA-compliant coverage.”

About HealthSherpa

HealthSherpa partners with large employers, insurers, as well as insurance agencies and agents to support consumers searching for, enrolling in and utilizing high quality, affordable health insurance coverage. HealthSherpa only sells ACA marketplace plans, which have built-in consumer protections, and since its founding in 2014, has enrolled over 3 million Americans in Affordable Care Act coverage. For more information, visit http://www.healthsherpa.com.

Share article on social media or email:

Business: Executives

Netrush Names Industry Veteran Tim Hershey as Chief Retail Officer

Leave a comment


News Image

Tim Hershey’s experience and industry knowledge will help us further accelerate the performance of our partners and stay ahead of the curve in the ever-changing retail landscape.


VANCOUVER, Wash. (PRWEB)

In response to continued growth and innovation in the e-commerce space, Netrush has announced the addition of Tim Hershey to the executive leadership team as the company’s Chief Retail Officer.

“Our retail operations are essential to how we help our partners win on Amazon and e-commerce,” said Netrush CEO Brian Gonsalves. “It’s humbling to watch the Netrush team grow to where we are today. Tim Hershey’s experience and industry knowledge will help us further accelerate the performance of our partners and stay ahead of the curve in the ever-changing retail landscape.”

Hershey has over 25 years of experience working with high-profile brands including Nike, Gucci, and Gap.

As Chief Retail Officer, Hershey will support the organization by driving mutually profitable, sustainable growth for Netrush and its premium partners. He’ll also be sharply focused on the growth and development of the company’s high-performing brand management and sales teams.

“Our brand partners already have the amazing product,” said Hershey. “When you take that and combine it with our expertise, there’s no end to the potential of what we can do. I’m excited to add my experience and knowledge to an already winning team.”

Netrush is an online retailer that partners with premium brands to provide the teams, technology, strategy, and infrastructure needed to thrive on Amazon and other e-commerce platforms. With headquarters in Vancouver, Washington, and processing facilities in Kentucky and Canada, Netrush provides a full suite of capabilities ranging from supply chain to creative services that make brands stand out across the shopping journey. For more information, visit http://www.netrush.com.

Share article on social media or email:

Health

NeoTract Designates Dr. Timothy Posey as UroLift® Center of Excellence

Leave a comment


News Image

“This designation recognizes Dr. Timothy Posey as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson


PLEASANTON, Calif. (PRWEB)

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Timothy Posey, MD, Urologic in Tupelo, MS, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Posey has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“This designation recognizes Dr. Timothy Posey as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are pleased to see the continued acceptance of the UroLift System as a standard of care treatment that may allow men to discontinue the use of BPH medications and improve their quality of life.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

health and fitness

Alloy Personal Training Franchise announces their first major development deal with several more deals imminent

Leave a comment


Alloy Personal Training Office

“Our nearly 30 years of experience coupled with the thousands of gyms we’ve worked with through our Alloy licensing company have given us a great business model for our partners,” says Alloy CEO Rick Mayo.


ROSWELL, Ga. (PRWEB)

Alloy Personal Training Franchise announced that they have awarded their first major development deal with several more deals imminent.

Alloy Personal Training, an award-winning personal training fitness business, launched their new franchise opportunity, Alloy Personal Training in September 2019, with a vision to provide a superior personal training franchise solution that is uniquely focused to serve the ever-growing “active aging” population, specifically those 50 years and older.

“We are excited to award our first franchise and have several other candidates that are in the final stages,” says Alloy CEO Rick Mayo. “Our nearly 30 years of experience coupled with the thousands of gyms we’ve worked with through our Alloy licensing company have given us a great business model for our partners.”

While The Alloy Personal Training Franchise Opportunity is just over four months old, the Alloy systems, platforms, and know-how have already been used to serve millions of members in thousands of fitness facilities around the world and was recently awarded the AFS Fitness Business of the Year.

“We have spent the last few years making significant changes to our previous fitness program license model to become a personal training franchise opportunity,” says Suzanne Robb, COO of Alloy Personal Training. “Our mission is to take our unique personal training system and build a personal training franchise that is strong, durable, and timeless. We believe the personal training and fitness industry needs an overhaul, and we want to be the force to make it happen.”

“The Alloy Personal Training Franchise opportunity includes everything that we have learned to own and operate a successful Personal Training Fitness Business,” says Tony Chemer, VP of Franchise Sales, “it allows us to provide total support for our business partners with all of the details required from build-out design, equipment, fitness operations, marketing, and the specifications of our systems that are already proven in thousands of gyms worldwide.”

Discovery days are underway, and territories are now being awarded. The Alloy systems are well developed, and focusing on discreet segments.

About Alloy Personal Training Franchise:

The Alloy Personal Training fitness program was created in 1992 around a very straightforward philosophy: people who get personalized coaching get better results. Today, Alloy programs are among the most effective programs in the world for helping people, especially those over 50, who want to look and feel their absolute best.

Alloy’s established, effective fitness platform and business management solutions have delivered real results throughout the world. Alloy Personal Training Franchise gives franchisees the chance to make an impact, both on their community and their future with a branded, brick-and-mortar Alloy personal training franchise location.

Share article on social media or email:

Industry: Healthcare

NeoTract Designates Dr. Greg Griewe as UroLift® Center of Excellence

Leave a comment


News Image

“We are proud to name Dr. Greg Griewe as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson


PLEASANTON, Calif. (PRWEB)

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Greg Griewe, MD, Pinehurst Surgical in Pinehurst NC, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Griewe has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are proud to name Dr. Greg Griewe as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “The UroLift System is a safe and effective treatment that allows physicians to treat men in-office under local anesthesia, so they can experience lasting symptom relief within days after receiving treatment.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Business: Executives

Toomey Chosen to Lead BKD Wealth Advisors After Thurman Announces Retirement Plans

Leave a comment


“I can’t say enough about the job Jack has done in developing the BKDWA practice, and we’ll miss his presence and charisma greatly. I look forward to seeing Steve continue growing as a firm leader as he forges ahead,” BKD CEO Ted Dickman said.


SPRINGFIELD, Mo. (PRWEB)

BKD CPAs & Advisors has selected Steve Toomey as the next managing partner of BKD Wealth Advisors, LLC (BKDWA), a subsidiary of BKD that provides investment oversight, wealth management and family office services to high-net-worth families and corporations. Toomey will succeed Jack Thurman, who has provided wealth management services since 1986.

Toomey will start his new position effective June 1, 2020, with Thurman’s planned retirement on May 31, 2021. During his final year, Thurman will focus on developing several significant client opportunities, including the critical transition planning of these relationships, allowing Toomey to effectively take the reins of BKDWA.

“I can’t say enough about the job Jack has done in developing the BKDWA practice, and we’ll miss his presence and charisma greatly. I look forward to seeing Steve continue growing as a firm leader as he forges ahead,” BKD CEO Ted Dickman said.

Thurman will work closely with Toomey to help ensure a unified approach to supporting clients and serving their needs. A strong succession plan is key to helping clients with upward mobility and continued success.

Share article on social media or email:

Health

Pivot Point Consulting Announces Advisory Board to Drive Growth Strategy

Leave a comment


Pivot Point Consulting’s Advisory Board Members Daniel Herman and Mike Sweeney

We’re grateful to have such experienced senior healthcare IT leaders at the table with us and look forward to growing our team of advisory board members to bring in other capabilities aligned with our services to shape what we’re doing today, as well as our future.


NASHVILLE, Tenn. (PRWEB)

Healthcare IT consulting leader, Pivot Point Consulting, a Vaco Company, announces a new Advisory Board to help shape and guide its growth strategy with the leadership team.

Comprised of CEOs and senior leaders of leading healthcare IT organizations, the Advisory Board will work with the leadership team to monitor trends shaping the industry and ensure market relevance and innovation given the changing healthcare ecosystem, as well as identify both strategic resources and acquisition opportunities.

The Advisory Board includes:

Daniel S. Herman, Founder of Aspen Advisors and former Managing Director of Informatics and Technology at The Chartis Group

Daniel founded and served as Managing Director of Aspen Advisors, an industry recognized information technology and operations improvement consulting firm comprised of over 130 professionals which merged with The Chartis Group in 2014. He also served as Senior Vice President in a privately held consulting firm (Dearborn Advisors, LLC), a Regional Vice President in a publicly traded healthcare information technology services firm (First Consulting Group), a manager in the healthcare consulting practice of a national CPA firm (KPMG) and an implementation manager for a healthcare software vendor (McKesson).

For more than 30 years, Daniel advised leading academic medical centers, integrated delivery networks, physician group practices, specialty providers and provider-sponsored managed care organizations on enhancing the value of their information technology investments. An early advocate for improving care delivery and operations through the effective use of technology, he is a Life Fellow of the Healthcare Information Management & Systems Society (HIMSS), served on the Board and as a past president in the Colorado, Greater Chicago and Western Pennsylvania HIMSS Chapters and has authored numerous articles and presentations on leadership, various aspects of Healthcare Information Technology Management and obtaining value from IT investments.

Mike Sweeney, former President and CEO of MaxIT Healthcare

Mike was the President and CEO of MaxIT Healthcare, which was acquired by Science Applications International Corporation (SAIC). MaxIT employed over 1,000 consultants and specialized in the implementation and optimization of electronic health record (EHR) systems from major software vendors for healthcare organizations across North America. He also served in senior executive positions at McKesson and at Esurg, a healthcare e-commerce business. Mike brings deep experience developing and delivering a range of healthcare IT services and solutions primarily to commercial hospital groups and other medical delivery organizations. He retired after the acquisition and now serves as a Board Director and Advisor to several companies.

“The Advisory Board illustrates Pivot Point Consulting’s commitment to exceptional quality and sustained growth. We’re grateful to have such experienced senior healthcare IT leaders at the table with us and look forward to growing our team of advisory board members to bring in other capabilities aligned with our services to shape what we’re doing today, as well as our future,” said Rachel Marano, Managing Partner.

About Pivot Point Consulting

Pivot Point Consulting enables healthcare organizations to realize the most value from their technology and data through their KLAS ranked advisory, implementation/optimization, managed services and talent solutions.

The company provides strategy and consulting services for providers, payers and life sciences organizations – with 450 employees serving 85+ clients across the United States. Pivot Point Consulting has earned many industry and workplace quality awards including: Top three Best in KLAS for HIT Implementation and Support for four years running (2015, 2016, 2017 and 2018), Highest Rated Vendor in KLAS Implementation Services in the Select Category (July 2017), #1 in KLAS for Epic Consulting in the Select Category (2016), #9 in Modern Healthcare’s Best Places to Work in 2016.

For more information about Pivot Point Consulting, visit https://pivotpointconsulting.com/. Follow us on LinkedIn.

Share article on social media or email: